Hengrui Pharmaceuticals announced that it plans to use its own funds to repurchase A-shares through centralized bidding, with a total repurchase amount of no less than 1 billion yuan and no more than 2 billion yuan, at a price not exceeding 81.78 yuan per share. The repurchased shares will be used for an employee stock ownership plan, and the repurchase period will be no more than 12 months from the date of board approval. The company also released its 2026 semi-annual report, achieving operating revenue of 15.456 billion yuan, down 1.94 percent year on year, and net profit attributable to shareholders of the listed company of 4.465 billion yuan, up 0.34 percent year on year. Among this, innovative drug sales revenue was 8.809 billion yuan, up 16.38 percent year on year, accounting for 63.16 percent of pharmaceutical sales revenue. In addition, the company plans to launch a 2026 A-share employee stock ownership plan, with a transfer price of 26.21 yuan per share, a quantity of no more than 12.855 million shares, accounting for about 0.19 percent of the company's total share capital, and a total of no more than 1,269 participants.
Jiangsu Hengrui Medicine Co LtdAnnounced A-share buyback of 1-2 billion yuan and employee stock ownership plan, supporting share price.
Hsino Tower Group Co., Ltd.
Suzhou Oriental Semiconductor Co. Ltd. A